What Is AI in Drug Discovery Compliance?

AI in drug discovery uses machine learning, statistical modeling and data-driven automation to improve target identification, hit discovery, lead optimization, clinical trial planning and safety monitoring. In this context, compliance means proving that AI systems are reliable, well-documented and fit for purpose while protecting data integrity, patient safety and scientific credibility.

• AI can accelerate drug discovery, but only if the underlying data, models and workflows are sufficiently transparent and reliable
• Regulators increasingly expect a risk-based approach that ties model validation to a specific context of use
• Documentation is central to compliance, including data provenance, version control, validation evidence and governance procedures
• Real-world applications are expanding across target identification, clinical development, manufacturing and pharmacovigilance
• Key limitations remain, including black-box behavior, biased data, reproducibility gaps and evolving global regulatory expectations

Why Is Compliance Important for AI in Drug Discovery?

AI is drawing significant attention in drug discovery because it can reduce costs, shorten timelines and improve decision-making across the development pipeline. These models can analyze large datasets to predict drug-target interactions, pharmacokinetics and toxicity, helping teams accelerate lead identification, lead optimization and clinical trial design.

To deliver value in regulated environments, however, AI platforms must align with requirements for data integrity, patient safety and ethical oversight. Agencies such as the FDA and EMA, along with established data governance standards, shape how organizations validate systems, manage records and document model performance. Key examples include:²

• 21 CFR Part 11: Emphasis on the reliability and integrity of electronic records
• FAIR Principles: Findable, Accessible, Interoperable and Reusable
• ALCOA and ALCOA+: Data management must comply with GMP (Good Manufacturing Practice), Attributable, Legible, Contemporaneous, Original and Accurate
• The Annex 11 (EU EMA): Emphasis on software and platform validation, audit trails and electronic signatures
• API (Application Programming Interface) of computerized platforms must maintain secure data exchange, traceability, documentation and version control
• The OQ (Operational Qualification): It addresses the importance of robustness and reproducibility of computer platforms

Taken together, these frameworks make one point clear: organizations using AI in drug discovery must be able to show how models are trained, validated, updated and governed over time.

What Does the AI Regulatory Framework Look Like in Drug Discovery?

An AI regulatory framework is the set of principles, guidance and operational requirements that govern how AI systems are developed, validated, deployed and monitored in drug discovery and development. Its purpose is to support data integrity, transparency, scientific validity and ethical use across the AI lifecycle.³

Compared with traditional drug development compliance frameworks, AI-specific oversight usually requires additional documentation and governance, including:⁴

• Training data
• Decision logic
• Algorithm versions
• Validation data
• The existence of black-box models

These requirements help protect the scientific validity, reproducibility and clinical relevance of AI-generated insights. Without them, organizations risk unreliable conclusions, reduced regulatory confidence and weaker support for AI adoption in drug development.⁴

What Does the FDA Expect for AI in Drug Development?

The FDA has released multiple guidance documents and guiding principles that shape how organizations approach AI safety, transparency and lifecycle oversight.⁵ Examples include:

• Artificial Intelligence and Machine Learning Software as a Medical Device (SaMD) Action Plan
• Good Machine Learning Practice for Medical Device Development: Guiding Principles
• Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles
• Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles
• Final Guidance: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions
• Draft Guidance: Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations

Although many of these documents focus on medical devices, their underlying principles are highly relevant to AI applications in diagnostics and drug discovery. In practice, the FDA’s expectations can be summarized as follows:⁶

• The purpose of the AI platform must be clearly outlined (e.g., diagnosis, target prediction)
• The potential impact or risks on patient safety must be disclosed
• The input data, training workflow, performance metrics and the decision-making logic must be explained
• The accuracy of the model must be demonstrated and documented
• All modifications and recalibration must be included in the report
• Protection measures for sensitive proprietary and patient information must be indicated

For pharma companies and research organizations, that means building a regulatory strategy early, strengthening data governance and improving model explainability from the start. Meeting these expectations typically requires close collaboration among data scientists, clinicians and regulatory teams.⁶

How Is AI Used in Drug Discovery in the Real World?

Beyond compliance planning, it is equally important to understand where AI is already creating value across the drug development lifecycle. In practice, adoption now extends well beyond early-stage molecule screening. In discovery, AI is used to prioritize targets, model structure-activity relationships and identify candidate compounds faster than conventional screening alone.

In clinical development, AI can support patient stratification, site selection and protocol optimization, especially when trial datasets are large and heterogeneous. In manufacturing and quality settings, AI may help identify process deviations earlier, while in pharmacovigilance and post-market monitoring, it can support signal detection and safety trend analysis.

Across all of these use cases, the core compliance requirement remains the same: organizations must define the model’s intended role, validate it for that context and maintain auditable oversight throughout its lifecycle.

What Are the Biggest Compliance Challenges in AI-Driven Drug Discovery?

Even with clearer guidance, meeting these expectations remains difficult in practice. Pharmaceutical companies and research organizations still face several recurring barriers when implementing compliant AI workflows.

How Do Data Quality and Integrity Affect AI Compliance?

AI model performance depends heavily on the quality and consistency of training data. Incomplete, biased or poorly annotated datasets can produce unreliable predictions and weaken regulatory confidence. To reduce that risk, organizations should implement strong data standardization, provenance tracking and traceability practices so regulators can follow how data were generated, processed and used.¹

Why Are Validation and Reproducibility So Important?

Validating AI algorithms requires rigorous testing to show that model performance is accurate, robust and repeatable under relevant conditions. Reproducibility remains a challenge, especially when models rely on proprietary architectures or poorly documented workflows. Clear documentation of datasets, parameters and version control is essential for building scientific credibility and supporting regulatory review.⁷

What Ethical Risks Come With AI in Drug Discovery?

Ethical concerns create another major barrier to approval. Bias in training datasets, including the underrepresentation of certain patient populations, can limit the generalizability of predictions in clinical settings.1 Privacy is a concern when teams handle patient-specific multi-omics data or health records. To mitigate risks, organizations should use secure storage, de-identification and privacy-compliant data practices regulations.⁸

Why Do Transparency and Explainability Matter?

Trust in AI depends on transparency. Regulators, developers and end users need a clearer view of how models use data, generate outputs and influence decisions. Explainable models and governance processes that monitor bias, performance drift and contradictory outputs can improve accountability and make regulatory review more efficient by clarifying the link between inputs, outputs and clinical relevance.⁹

What Limits AI Adoption in Drug Discovery?

• Limited interpretability: High-performing models may still be difficult to explain, which can slow regulatory review and reduce confidence in high-impact decisions
• Dataset bias and representativeness gaps: If training data do not reflect relevant populations, disease biology or experimental conditions, model outputs may not generalize reliably
• Reproducibility challenges: Results can vary when datasets, preprocessing steps or model parameters are not adequately controlled or documented
• Evolving regulatory expectations: Guidance is advancing quickly, which means governance processes built today may need frequent updates
• Operational burden: Sustained compliance requires cross-functional teams, version control, audit readiness and lifecycle monitoring, all of which can strain internal resources.

How Can Companies Stay Compliant When Using AI in Drug Discovery?

As expectations evolve, maintaining compliance in AI-driven drug discovery demands proactive regulator engagement and robust governance. Pharma should align data, training and validation with GMLP and document each step. Early and ongoing regulator dialogue helps teams anticipate needs and minimize approval risks.⁵

Sustained compliance also depends on collaboration among AI developers, data scientists, clinicians and regulatory professionals. That cross-functional alignment helps ensure that technical innovation remains connected to patient safety, ethical standards and regulatory expectations.¹

Regulatory compliance should also extend beyond initial approval. AI platforms need continuous performance monitoring, periodic revalidation and updated documentation after deployment. A lifecycle management framework with defined update procedures can help organizations maintain compliance over time.¹⁰

References

1. Mirakhori F, Niazi SK. Harnessing the AI/ML in drug and biological products discovery and development: the regulatory perspective. Pharmaceuticals 2025;18(1):47.
2. Kuthuru A. Pharmaceutical Research Databases: Balancing AI Innovation with Regulatory Compliance. JCSTS 2025;7(4):822-828.
3. Ferreira FJ, Carneiro AS. AI-Driven Drug Discovery: A Comprehensive Review. ACS omega 2025.
4. Ajmal C, Yerram S, Abishek V, Nizam VM, Aglave G, Patnam JD, et al. Innovative approaches in regulatory affairs: leveraging artificial intelligence and machine learning for efficient compliance and decision-making. The AAPS Journal 2025;27(1):22.
5. Niazi SK. The coming of age of AI/ML in drug discovery, development, clinical testing, and manufacturing: the FDA perspectives. Drug Des Devel Ther 2023:2691-2725.
6. Joshi G, Jain A, Araveeti SR, Adhikari S, Garg H, Bhandari M. FDA-approved artificial intelligence and machine learning (AI/ML)-enabled medical devices: an updated landscape. Electronics 2024;13(3):498.
7. Higgins DC, Johner C. Validation of artificial intelligence containing products across the regulated healthcare industries. Ther Innov Regul Sci 2023;57(4):797-809.
8. Luo X, Chen F, Chen Y, Zhou Q. Ethical and regulatory aspects of artificial intelligence in drug design. Deep Learning in Drug Design: Elsevier; 2026:443-458.
9. Mourya A, Jobanputra B, Pai R. AI-powered clinical trials and the imperative for regulatory transparency and accountability. Health Technol 2024;14(6):1071-1081.
10. Khinvasara T, Tzenios N, Shanker A. Post-market surveillance of medical devices using AI. J Altern Complement Med 2024;25(7):108-122.
11. Sangaraju VV. AI and Data Privacy in Healthcare: Compliance with HIPAA, GDPR, and emerging regulations. IJETTCS 2025:67-74.